The NeoTYPE Brain Tumor Profile analyzes 61 biomarkers through a combination of next-generation sequencing (NGS), other molecular methods, FISH, and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions.
NGS (50 genes + 2 biomarkers): AKT1, APC, ATRX, BCOR, BCORL1, BRAF, CDK6, CDKN2A, CIC, CTNNB1, EGFR, EGFRvIII, EPCAM, ERBB2, ERBB4, FGFR1, FGFR1 fusions, FGFR2, FGFR2 fusions, FGFR3, FGFR3 fusions, FUBP1, H3F3A (H3-3A), HIST1H3C (H3C3), HRAS, IDH1, IDH2, KRAS, MAP2K1, MET, Microsatellite Instability (MSI), MLH1, MSH2, MSH6, MYC, MYCN, NF1, NF2, NRAS, NTRK1 fusions, NTRK2 fusions, NTRK3 fusions, PIK3CA, PMS2, PTCH1, PTEN, RAF1 fusions, RB1, SETD2, SMAD4, SMO, SRC, TERT Promoter, TP53, Tumor Mutation Burden (TMB), VHL
- Other Molecular (1 gene): MGMT Promoter Methylation Analysis
- FISH (6 FISH): 1p/19q Deletion, BRAF, MET, MYCN, PDGFRA, PTEN (tech-only available)
- IHC (1 biomarker): PD-L1 LDT (tech-only available)
The NeoTYPE Brain Tumor Profile characterizes primary or metastatic brain tumors of any histological subtype for the most significant genetic changes relevant to diagnosis, therapy decisions, prognosis, and clinical research. It is appropriate for patients with newly-diagnosed or recurrent disease and patients with an atypical clinical presentation.
- FFPE tissue: Paraffin block preferred. Please use 10% buffered formalin fixative. Do not use zinc fixatives.
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Slides can be packed at room temperature.